AG真人官方

STRATA Skin Sciences to Present at the聽H.C. Wainwright 27th Annual Global Investment Conference

HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (鈥淪TRATA鈥� or the 鈥淐ompany鈥�) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and CEO of Strata Skin Sciences will present a corporate overview at the H.C. Wainwright 27^th Annual Global Investment Conference. The conference is being held on September 8 鈥� 10, 2025 at the Lotte New York Palace Hotel.

Dr. Rafaeli鈥檚 presentation will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting and to register for the conference, click below:

About聽STRATA Skin Sciences, Inc.

STRATA Skin Sciences聽is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^庐聽excimer laser, VTRAC^庐聽lamp systems, and the TheraClear^庐X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the聽U.S.聽through its unique Partnership Program. STRATA鈥檚 popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company鈥檚 plans, objectives, expectations and intentions and may contain words such as 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥渟eeks,鈥� and 鈥渆xpects,鈥� that suggest future events or trends. These statements, the Company鈥檚 ability to launch and sell products recently acquired or to be developed in the future, the Company鈥檚 ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company鈥檚 ability to build a leading franchise in dermatology and aesthetics, are based on the Company鈥檚 current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company鈥檚 expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company鈥檚聽SEC聽reports on Forms 10-Q and 10-K. Given聽such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC聽disclosures available at聽听补苍诲听.

Investor Contact:
CORE IR
516-222-2560